Therapeutic effect of intensive granulocyte and monocyte adsorption apheresis combined with thiopurines for steroid- and biologics-naïve Japanese patients with early-diagnosed Crohn’s disease

Takumi Fukuchi1, Hiroshi Nakase2*, Satoshi Ubukata1, Minoru Matsuura2, Takuya Yoshino2, Takahiko Toyonaga2, Keiji Shimazu3, Hideaki Koga1, Hiroshi Yamashita1, Dai Ito1 and Kiyoshi Ashida1

Abstract

Background: Early induction with biologics can reduce complications in patients with Crohn’s disease (CD) and improve their quality of life. The safety of biologics, however, is uncertain. Granulocyte and monocyte adsorptive apheresis (GMAA) is a natural biologic therapy that selectively removes granulocytes and monocytes/macrophages and has few severe adverse effects. The effects of GMAA on patients with early-diagnosed CD are unclear. We investigated the effects of GMAA combined with thiopurines on patients with early-diagnosed CD.

Methods: Twenty-two corticosteroid- and biologic-naïve patients with active early-diagnosed CD were treated with intensive GMAA (twice per week) combined with thiopurines administration. Active early-diagnosed CD was defined as follows: (i) within 2 years after diagnosis of CD, (ii) with no history of both surgical treatment and endoscopic dilation therapy, and (iii) Crohn’s Disease Activity Index (CDAI) was higher than 200. We investigated the ratios of clinical remission defined as CDAI was less than or equal to 150 at 2, 4, 6 and 52 weeks and mucosal healing defined as a Simplified Endoscopic Activity Score for Crohn’s Disease (SES-CD) as 0 at 6 and 52 weeks. Adverse events were recorded at each visit.

Results: The ratios of clinical remission at 2, 4, and 6 weeks were 6 of 22 (27.2%), 12 of 22 (54.5%), and 17 of 22 (77.2%), respectively. At 52 weeks, 18 of 21 patients (81.8%) were in clinical remission. The ratios of mucosal healing at 6 and 52 weeks were 5 of 22 (22.7%) and 11 of 22 (50%), respectively. The difference in the mucosal healing ratio was significant between 6 and 52 weeks (p = 0.044). No serious adverse effects were observed during this study.

Conclusions: Combination therapy with intensive GMAA and thiopurines administration rapidly induced high remission in patients with active early-diagnosed CD without serious adverse effect. Mucosal healing was observed in 50.0% of enrolled patients. This combination therapy might be a rational option for patients with early-diagnosed CD.

Keywords: Crohn’s disease, Granulocyte and monocyte adsorptive apheresis, Thiopurines, Mucosal healing

* Correspondence: hiropy_n@kuhp.kyoto-u.ac.jp

2Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University Hospital, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan

© 2014 Fukuchi et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article unless otherwise stated.
Background
Crohn’s disease (CD) is a chronic inflammatory disorder of unknown etiology. The current practice guidelines are designed to maintain remission with optimal medication after induction therapy due to the potential for repeated relapse in patients with CD [1,2].

Corticosteroids effectively suppress acute CD flares. Approximately 60% of patients will have a complete response during the short-term outcome (30 days) of a first course of steroids [3]. Long-term exposure to corticosteroids, however, is problematic due to dependency and/or the development of resistance [4].

In the last 15 years, the advent of biologic therapies, such as anti-tumor necrosis factor (TNF)-α, has improved the management of refractory CD. In addition, the efficacy of TNF-α antagonists suggests a new concept that early induction with intensive therapy may reduce complications associated with conventional treatment and improve the patient’s quality of life [5]. In this regard, intensive therapy with early use of this biologic agent has been proposed and is known as ‘top-down’ therapy. Early use of anti-TNF therapy, however, is associated with the development of serious life-threatening infections in addition to other well-documented hematologic, immunologic, cardiovascular, and malignant adverse effects [6]. Therefore, whether long-term use of anti-TNF therapy is suitable for all patients with CD remains unclear.

A 2-year open-label randomized trial by D’Haens et al. [5] showed that short-term infliximab (IFX) combined with azathioprine (AZA) or 6-mercaptopurine was more effective than conventional management for the induction of remission and reduction of corticosteroid use in patients recently diagnosed with CD, and patients treated with early combined immunosuppression had consistently higher rates of remission than controls within the first year of treatment. The findings from this study suggest that early use of immunomodulators following optimal induction therapies has favorable effects on active CD. In addition, recent Hungarian population-based inception cohort [7] showed that a reduction in the surgical ratio in patients with CD was independently associated with increased early use of thiopurines. Thus, the development of promising induction therapies with thiopurines is expected for patients with CD to avoid complications related to various drugs as much as possible.

The therapeutic effects and safety of granulocyte and monocyte adsorptive apheresis (GMAA) with the Adacolumn (JIMRO, Takasaki, Gunma, Japan) for patients with inflammatory bowel disease (IBD) have been much focused because this system can be expected to be a natural biologic therapy in that selectively removing granulocytes and monocytes/macrophages from the peripheral blood leads to decreased production of inflammatory cytokines [8-10]. Recent data demonstrated that ulcerative colitis (UC) patients treated with a twice-a-week regimen (intensive GMAA) could achieve significantly higher ratios of clinical remission and mucosal healing compared with an once-a-week regimen (weekly GMAA) [11,12]. In addition, it was reported that therapeutic effect of GMAA with 10 sessions on active UC patients was superior to that with 5 sessions [13,14]. Thus, intensive GMAA with 10 sessions might be an optimal therapy for the induction of remission in patients with CD as well as UC.

In the present study, we prospectively followed patients with newly diagnosed CD for 1 year after administering intensive GMAA combined with thiopurines, focusing on clinical remission and endoscopic activity.

Methods
Patients
From January 2010 to August 2012, a total of 22 corticosteroid- and biologics-naïve patients with moderate to severe active early-diagnosed CD were enrolled in the study. Early-diagnosed CD was defined as follows: (i) diagnosis within the past 2 years, (ii) patients with CD and a past history of surgery and endoscopic dilation for CD were excluded. The diagnosis of CD was based on clinical, endoscopic, radiologic, and histologic findings. Fecal bacteria culture yielded no specific pathogens in any of the patients. Patients older than 17 years of age with active early-diagnosed CD were consecutively recruited if they had newly or relapsing active disease. Moderate-to-severe active CD was defined as a Crohn’s Disease Activity Index (CDAI) [15] higher than 200. Oral aminosalicylates were only permitted if given at a stable dose. None of the patients had undergone previous treatment with corticosteroids or TNF-α antagonists (Table 1).

Treatment
All 22 patients with early-diagnosed CD were treated by GMAA combined with thiopurines administration. Intensive GMAA treatment (twice per week, 10 sessions) was performed as previously described [11,12,16] for all patients with CD. Blood was accessed via the antecubital vein in one arm, and from the outflow blood was returned to patients via the antecubital vein in the other arm through 19 gauge needles. The apheresis session was performed at a flow rate 30 mL/min for 60 min, aiming to expose 1800 mL blood/session. Anti-coagulation for GMAA therapy was induced by heparin sodium. Thiopurines were administered to all 22 patients at the start of GMAA therapy. The dose of thiopurines was adjusted to aim for a white blood cell count <5000/mL. Patients responding to treatment with intensive GMAA kept receiving thiopurines drugs for 52 weeks from the end of the intensive GMAA.
2.5 mg. During this study, adverse events were recorded at each visit.

The protocol and patients’ informed consent forms were reviewed and approved by the Institutional Review Board at Osakafu Saiseikai Nakatsu Hospital. The study was conducted in accordance with the Declaration of Helsinki, the consolidated Good Clinical Practice Guidelines, and the applicable regulatory requirements.

Assessment of endoscopic severity

All 22 patients with early-diagnosed CD underwent ileocolonoscopic examinations before, and at 6 and 52 weeks after treatment. Endoscopic severity of CD was assessed using the Simplified Endoscopic Activity Score for Crohn’s Disease (SES-CD) [17].

Assessment

Primary efficacy was evaluated based on the clinical remission rate at 2, 4, and 6 weeks during intensive GMAA, and 13, 26, and 52 weeks after starting treatment. Clinical remission was defined as CDAI ≤ 150. Secondary efficacy was evaluated based on SES-CD, complete mucosal healing rate, and mean C-reactive protein (CRP) values at weeks 6 and 52. Complete mucosal healing was defined as a SES-CD of 0 [18]. If patients received rescue treatment such as intensive GMAA again, corticosteroids, or biologics because of clinical relapse of CD, their treatment was considered to have failed.

Statistical analysis

Data are presented as mean ± SE. Categorical and continuous data were compared using a two-tailed Fisher exact test and Student’s t-test. A p value of less than 0.05 was considered statistically significant.

Results

Clinical characteristics

The clinical characteristics of patients with early-diagnosed CD enrolled in this study are summarized in Table 1. Mean patient age was 39.5 ± 2.9 years, mean patient disease duration was 5.8 ± 1.8 months (range 1–32 months), and mean CDAI was 260.0 ± 10.5. Disease location was the colon in 13 (59.1%), colon/ileum in 3 (13.6%), and ileum in 6 (27.3%). Mean SES-CD was 9.4 ± 0.9 (range 5–19). Of the 22 patients, 5 patients (22.7%) were treated with a stable dose (3000 mg) of 5-ASA. None of patients enrolled in the study had been treated previously with corticosteroids, thiopurines, or biologics (Table 1).

Clinical efficacy

The ratios of clinical remission at 2, 4, and 6 weeks were 6 of 22 (27.2%), 12 of 22 (54.5%), and 17 of 22 (77.2%), respectively (Figure 1). Mean time and number of GMAA sessions to clinical remission were 28.0 ± 2.9 days and 7.3 ± 0.6 sessions, respectively, in patients with CD who achieved clinical remission during intensive GMAA. One patient with colonic structure and 1 of 2 patients with perianal disease did not achieve clinical remission during intensive GMAA. The ratios of clinical remission at 13 weeks and 26 weeks were 18 of 22 (81.8%) and 19 of 22 patients (86.4%), respectively. At 52 weeks, 18 of 22 patients (81.8%) were in clinical remission (Figure 1).

During this study, two patients were treated with adalimumab because of non-response to intensive GMAA and two patients required intensive GMAA again because of CD flares.

Evaluation of mucosal healing

Mean SES-CD scores in all patients are shown in Figure 2-A. Mean SES-CD scores were compared at three time points (0, 6, and 52 weeks). The scores were significantly different between 0 and 52 weeks. In addition, the ratios of mucosal healing at 6 and 52 weeks were 5 of 22 (22.7%) and 11 of 22 (50%), respectively (Figure 2-B).

Table 1 Clinical parameters of patients with early-diagnosed Crohn's disease treated by intensive granulocyte and monocyte adsorptive apheresis combined with thiopurines therapy

| Parameter                | Value                  |
|--------------------------|------------------------|
| Age (years)              | 39.5 ± 2.9             |
| Sex (men/women)          | 18/4                   |
| Disease duration (months)| 5.8 ± 1.8              |
| Disease location         |                        |
| Colon                    | 13 (59.1)              |
| Colon/ileum              | 3 (13.6)               |
| Ileum                    | 6 (27.3)               |
| Disease behavior         |                        |
| Inflammatory             | 22 (100)               |
| Structure                | 1 (4.5)                |
| Perforation              | 0                      |
| Perianal disease         | 2 (9.1)                |
| Previous treatment       |                        |
| 5-ASA                    | 5 (22.7)               |
| Thiopurines              | 0                      |
| Corticosteroids          | 0                      |
| Biologics                | 0                      |
| CDAI                     | 260.0 ± 10.5           |
| SES-CD                   | 9.4 ± 0.9              |
| CRP (mg/dl)              | 3.5 ± 0.7              |

Number of patients is shown for sex, disease location, disease behavior, perianal disease and previous treatment. Data are presented as mean ± SE for age, disease duration, CDAI, SES-CD, and CRP. 5-ASA 5-aminosalicylate; CDAI, Crohn's disease activity index; SES-CD, Simple endoscopic score of Crohn's disease. Values in parenthesis on vertical line are percentages of all 22 patients with early-diagnosed CD.
ratio of mucosal healing between 6 and 52 weeks were significantly different.

**Change in CRP values by treatment**
At 6 weeks after starting treatment, the mean CRP for all patients decreased significantly from 3.5 ± 0.7 to 0.4 ± 0.1 mg/dl (p = 0.00003). At 52 weeks, mean CRP in patients followed for 52 weeks was 0.2 ± 0.1 mg/dl. Serum CRP levels differed significantly between before treatment and 52 weeks (p = 0.0002).

**Safety**
Two patients complained of nausea, but their symptoms improved following a dose reduction of thiopurines. No other serious adverse effects were observed during this study.

**Discussion**
In the present study we firstly demonstrated that intensive GMAA in combination with thiopurines resulted in higher ratios of clinical remission and mucosal healing at 52 weeks in corticosteroid- and biologics-naïve patients with early-diagnosed CD. This clinical study was of small size, however, expected to demonstrate the efficacy and safety of the combination therapy of GMAA and thiopurines.

The Study of Biologic and Immunomodulator Naïve Patients in Crohn’s Disease (SONIC) demonstrated that
IFX in combination with AZA was superior to IFX mono-
therapy for patients not treated previously with AZA [19].
An open-labeled clinical trial reported by D’Haens et al.
[5] showed the combination therapy (immunomodulators in
combination with three infusions of IFX at 0, 2, and 6 weeks) resulted in
a significantly higher clinical remis-

sion rate in patients with early-diagnosed CD compared
with conventional medication. These data suggest the im-
portance of optimal induction therapies with thiopurines
for patients with early-diagnosed CD.

In this study, we performed intensive GMAA (twice per
week) as an alternative to weekly GMAA as an induction
therapy. Previous data on the ratios of the induction of
remission in active CD refractory to corticosteroids by
weekly GMAA vary (30%-60%) [20-22]. Thus, the efficacy
of GMAA therapy on active CD patients as an induction
therapy has not been established. On the contrary, the re-
markable usefulness of intensive GMAA for the induction
of remission and mucosal healing in patients with active
UC compared with weekly GMAA suggests that the
therapeutic effects of GMAA are associated with fre-
quency of therapy per week [11,12]. In fact, our data
showed that this combination therapy as an induction
treatment in patients with active CD showed a remission rate comparable to that of corticosteroids or biologics
reported in controlled trials [3,5,19]. The therapeutic out-
come of intensive GMAA in this study might be due to
not only the GMAA frequency per week, but also the
population of eligible patients (corticosteroid- and bi-
ologics-naive early-diagnosed CD). In this regard, intensive
GMAA with thiopurines can be a promising induction
therapy for patients with early-diagnosed CD. Addition-
ally, there were no adverse effects related to GMAA in
this study. The induction of remission by GMAA in the
patients with early-diagnosed CD would have the advan-
tage in the point of avoiding adverse effects related to cor-
ticosteroid and biologics.

Several studies have demonstrated the efficacy of im-
munomodulators to prevent relapse in patients with CD
and showed that early use of immunomodulators de-
creases the cumulative surgical rate in patients with CD
[5,7,23]. In the present study, maintenance treatment
with thiopurines increased the clinical remission rate in
patients with early-diagnosed CD after treatment with
intensive GMAA. Also, our data demonstrated an ex-
trremely high clinical remission rate at 52 weeks (81.8%)
in CD patients treated with combination therapy in
comparison with previous reports. In this regard, the dif-
terence in the number and characteristics of the enrolled
patients may account for the differences in the clinical
remission ratio between the present study and previous
data. In this study, how treatment with thiopurines
could involve in having CD patients keep remission re-
mains unclear. Therefore, future clinical trial comparing
the relapse-free survival of CD patients achieving remis-

sion by GMAA who receive thiopurines with those who do not should be required. This head to head trial might elucidate who requires thiopurines among patients with early-diagnosed CD achieved clinical remission after
GMAA.

It should be noted that recent two clinical trials demon-
strated that very early administration of AZA is not effec-
tive for corticosteroid free-clinical remission in patients
with newly diagnosed CD [24,25]. However, one trial (the
GETAID group) showed that approximately 60% of CD
patients in the conventional management group finally re-
quired any immunosuppressive drugs for corticosteroid
free-clinical remission in a 3-year study period and the
occurrence of perianal lesions was significantly lower in
the AZA-treated group than in the conventionally-treated


group [24]. In addition, another trial (the AZTEC study

group) reported that early AZA therapy is more effective
for preventing a moderate to severe relapse in a post hoc
analysis [25]. Thus, these two reports did not necessarily
deny the effect of AZA in the treatment for CD patients
[24,25], but we should realize that these two clinical trials
suggest the importance of identifying when AZA would
be started in the population of CD patients whose disease
activity becomes progressive without optimal immuno-

suppressive treatments.

Recently, mucosal healing has been focused as a pre-
dictive marker of sustained remission irrespective of no
demonstration of clinical benefit of achieving complete
mucosal healing [18,25,27,28]. Rutgeerts et al. [26] reported
the value of an endoscopic score to predict recurrent CD.
In addition, Baert et al. [18] demonstrated the importance
of mucosal healing defined as SES-CD 0, based on a sig-
ificant difference in the steroid-free remission ratio after
therapy between patients with CD with SES-CD 0 and
SES-CD 1–9. In the present study, we prospectively exa-
mined mucosal healing in patients with CD treated with
combination therapy. We observed that ratios of mucosal
healing at 6 and 52 weeks were 22.7% and 50.0%, res-
pectively, and that at 52 weeks was comparable to data
reported by D’Haens et al. [27] and Colombel et al. [19].
Thus, our and D’Haens et al. [27] data might suggest
the usefulness of early induction with thiopurines in
biologics-naive patients with CD after induction with
optimal therapy, such as intensive GMAA, although we
should consider that the timing of the evaluation of muco-
sal healing varied depending on the medical treatment
and the characteristics of the enrolled patients.

The overall incidence of adverse events was related to
thiopurines, and not intensive GMAA. It was reported
that the combination of thiopurines and anti-TNF biologic
agents increases the relative risk of serious and opportu-
nistic infections [28]. Also, the use of corticosteroids may
further increase the relative risk of infections [3]. GMAA
is a natural biologic therapy for the patients with IBD and has few severe adverse effects. In the point of avoiding serious side effect and being performed repeatedly and safely, GMAA might be more advantageous than anti-TNF or corticosteroids. Therefore, intensive GMAA is considered to be an induction therapy alternative to corticosteroids and three infusions of IFX (at 0, 2, and 6 weeks).

Conclusions
Our findings showed that the combination therapy with intensive GMAA and thiopurines was an effective and well-tolerated therapeutic option for inducing and maintaining clinical remission in patients with early-diagnosed CD. The data, however, were derived from an open study including only a small number of patients, and did not address whether intensive GMAA with thiopurines for biologics-naïve patients with early-diagnosed CD was superior to corticosteroids and IFX. Therefore, future prospective studies with larger numbers of patients are required to assess the efficacy and safety of this combination therapy.

Abbreviations
CD: Crohn's disease; TNF: Tumor necrosis factor; IFX: Infliximab; AZA: Azathioprine; GMAA: Granulocyte and monocyte adsorptive apheresis; IBD: Inflammatory bowel disease; UC: Ulcerative colitis; CDAI: Crohn's disease activity index; SES-CD: Simplified endoscopic activity score for Crohn's disease; CRP: C-reactive protein.

Competing interests
The authors declare that they have no competing interests.

Authors' contributions
TF, SU: Patients management, conception, study design, acquisition and interpretation of the data, statistics, drafting, and preparation of the final. HN, MM, TY, and TT: Conception, study design, drafting, and review of the final manuscript. KS, HK, HY, DI and KA: Patients management, acquisition and interpretation of the data, and review of the final manuscript. All authors read and approved the final manuscript.

Acknowledgment
We thank Dr. Atsuo Tanaka, Dr. Ryota Yokota and Dr. Megumi Iwata (Department of Nephrology, Osakafu Saiseikai Nakatsu Hospital) and all of the other staff of the Dialysis Center, Osakafu Saiseikai Nakatsu Hospital, for performing the GMAA.

Author details
1Department of Gastroenterology and Hepatology, Osakafu Saiseikai Nakatsu Hospital, 2-10-39 Shibata, Kita-ku, Osaka 530-0012, Japan. 2Department of Nephrology, Osakafu Saiseikai Nakatsu Hospital, 2-10-39 Shibata, Kita-ku, Osaka 530-0012, Japan.

Received: 24 February 2014 Accepted: 8 July 2014 Published: 11 July 2014

References
1. Summers RW, Switz DM, Sessions JT Jr, Becktel JM, Best WR, Kern FJR, Singleton JW: National cooperative Crohn's disease study: results of drug treatment. Gastroenterology 1979, 77:847–869.
2. Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H, Jesdinsky H: European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984, 86:249–266.
3. Faubion WA Jr, Loftus EV, Harmsen WS, Zinsmeister AR, Sandborn WJ: The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001, 121:255–260.
4. Munkholm P, Langholz E, Davidsen M, Binder V: Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994, 35:360–363.
5. D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Strit L, Donner A, Vermeire S, Van de Mierop FJ, Coche JC, van der Woude J, Ochsenukh T, van Bodeggen AA, Van Hoevgegenn PP, Lamblecht GL, Mana F, Rutgeerts P, Feagin BG, Hommes D: Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomized trial. Lancet 2006, 371:660–667.
6. Lin J, Ziling D, Desai S, Kim S, Wong M, Korin Y, Braun J, Reed E, Gertsen D, Singh RR: TNFα blocker in human disease: An overview of efficacy and safety. Clin Immunol 2008, 126:13–30.
7. Lakatos PL, Golovics PA, David G, Pandur T, Erdely Z, Horvath A, Mester G, Balogh M, Szitocz I, Molnar C, Komaromi E, Veres G, Lovasz BD, Szathmari M, Kiss LS, Lakatos I: Has there been a change in the natural history of Crohn's disease? Surgical rates and medical management in a population-based inception cohort from Western Hungary between 1977-2009. Am J Gastroenterol 2012, 107:579–588.
8. Shimoyama T, Sawada K, Hitawashi N, Sawada T, Matsueda K, Munakata A, Asakura H, Tanaka T, Kasukawa R, Kimura K, Suzuki Y, Nagamachi Y, Muto T, Nagawa H, Iizuka B, Baba S, Nasu M, Kataoka T, Kashiwagi N, Sanabadi AR: Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apher 2001, 16:1–9.
9. Sanabadi AR, Hanai H, Takeuchi K, Umemura K, Nakashima M, Adachi T, Shima C, Bjarnason I, Lofberg R: Adacolumn an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of on inflammatory and refractory disease associate with leukocytes. Ther Apher Dial 2003, 7:48–59.
10. Hanai H, Watanabe F, Takeuchi K, Iida T, Yamada M, Iwakoa Y, Sanabadi A, Matsushita I, Saty S, Tozawa K, Arai H, Furuta T, Sugimoto K, Bjarnason I: Leukocyte apheresis for the treatment of active ulcerative colitis: a prospective uncontrolled pilot study. Clin Gastroenterol Hepatol 2003, 128–35.
11. Sakuraba A, Motoya S, Watanabe K, Nishishita M, Kane K, Matsui T, Suzuki Y, Oshima T, Kunioki R, Matsumoto T, Hanai H, Fukunaga K, Yoshimura N, Chiba T, Funakoshi S, Aoyama N, Andoh A, Nakase H, Mizuta Y, Suzuki R, Akimoto T, Iizuka M, Ashida T, Hibi T: An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol 2009, 104:2000–2005.
12. Iizuka M, Ashida H, Tani H, Ito D, Yamashita K, Matsuura M, Nagatani Y, Koga H, Send S, Eguchi T, Uebukata S, Kawagushi S, Ueda A, Tanaka T, Ohashi R, Otsuka M, Ashida K: Rapid induction of mucosal healing by intensive granulocyte and monocyte adsorptive apheresis in active ulcerative colitis patients without concomitant corticosteroid therapy. Aliment Pharmacol Ther 2011, 34:583–585.
13. Hanai H, Watanabe F, Yamada M, Sato Y, Takeuchi K, Iida T, Tozawa K, Tanaka T, Maruyama Y, Matsushita I, Iwakoa Y, Kikuchi K, Sanabadi AR: Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis. Digestion 2004, 70:35–44.
14. Kanke K, Nakano M, Hirasui H, Terano A: Clinical evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis. Dig Liver Dis 2004, 36:811–817.
15. Best WR, Becktel JM, Singleton JW, Kern F Jr: Development of a Crohn’s disease activity index. Gastroenterology 1976, 70:439–444.
16. Fukuchi T, Nakase H, Matsuura M, Yoshino T, Toyonaga T, Ohmori K, Uebukata S, Ueda A, Eguchi T, Yamashita H, Ito D, Ashida K: Effect of intensive granulocyte and monocyte adsorptive apheresis in patients with ulcerative colitis positive for cytomegalovirus. J Crohn’s Colitis 2013, 7:803–811.
17. Daperno M, D’Haens G, Van Assche G, Baert F, Bulots P, Maunoury V, Sostegni R, Rocca R, Pera A, Govers A, Mary JO, Colombel JF, Rutgeerts P: Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-GD. Gastrointest Endosc 2004, 60:505–512.
18. Baert F, Moortgat L, Van Asche G, Caenepeel P, Vergauwe P, De Vos M, Stokkers P, Hommes D, Rutgeerts P, Vermeire S, D’Haens G: Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. Gastroenterology 2010, 138:463–468.

19. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D’Haens G, Diamond RH, Brousard DL, Tang KL, van der Woude CJ, Rutgeerts P: Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010, 362:1383–1395.

20. Fukuda Y, Matsui T, Suzuki Y, Kanke K, Matsumoto T, Takazoe M, Matsumoto T, Motoya S, Honma T, Sawada K, Yao T, Shimoyama T, Hibi T: Adsorptive granulocyte and monocyte apheresis for refractory Crohn’s disease: an open multicenter prospective study. J Gastroenterol 2004, 39:1158–1164.

21. Ljung T, Thomsen OØ, Vatn M, Karlén P, Karlsen LN, Tysk C, Nilsson SU, Kilander A, Gillberg R, Löfberg R: Granulocyte and monocyte/macrophage apheresis for inflammatory bowel disease: the first 100 patients treated in Scandinavia. Scand J Gastroenterol 2007, 42:221–227.

22. Bresci G, Romano A, Mazzoni A, Scatena F, Altomare E, Capria A, Sacco R: Feasibility and safety of granulocytapheresis in Crohn’s disease: a prospective cohort study. Gastroenterol Clin Biol 2010, 34:682–686.

23. Bouhnik Y, Lémann M, Mary JY, Scemama G, Taï R, Matuchansky C, Modigliani R, Rambaud JC: Long-term follow-up of patients with Crohn’s disease treated with azathioprine or 6-mercaptopurine. Lancet 1996, 347:215–219.

24. Cosnes J, Bourrier A, Laharie D, Nahon S, Bouhnik Y, Carbonnel F, Allez M, Dupas JL, Reimund JM, Savoye G, Jouet P, Moreau J, Mary JY, Colombel JF: Early administration of azathioprine vs conventional management of Crohn’s disease: a randomized controlled trial. Gastroenterology 2013, 145:758–765.

25. Paniés J, López-Sanromán A, Bermejo F, García-Sánchez V, Esteve M, Torres Y, Domènech E, Piqueras M, Gomez-García M, Gutiérrez A, Taxonera C, Sans M: Early azathioprine therapy is no effective than placebo for newly diagnosed Crohn’s disease. Gastroenterology 2013, 145:766–774.

26. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M: Predictability of the postoperative course of Crohn’s disease. Gastroenterology 1990, 99:956–963.

27. D’Haens G, Geboes K, Rutgeerts P: Endoscopic and histologic healing of Crohn’s (ileo-) colitis with azathioprine. Gastrointest Endosc 1999, 50:667–671.

28. Toruner M, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, Colombel JF, Egan LJ: Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008, 134:929–936.

doi:10.1186/1471-230X-14-124
Cite this article as: Fukuchi et al.: Therapeutic effect of intensive granulocyte and monocyte adsorption apheresis combined with thiopurines for steroid- and biologics-naïve Japanese patients with early-diagnosed Crohn’s disease. BMC Gastroenterology 2014 14:124.

Submit your next manuscript to BioMed Central and take full advantage of:

• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit